In a recent expert-led presentation at the Practial Updates in Primary Care Virtual Series, Seth S. Martin, MD, MHS, and Daniel E. Soffer, MD, reviewed current evidence and clinical strategies for using...
A recent report from a non-profit, independant research group addresses the cost-effectiveness and budgetary impact of treatment with PCSK9 inhibitors.
An FDA advisory committee has voted to recommend approval of a new drug for the long-term treatment of patients with hypercholesterolemia and dyslipidemia.
